van der Straten Lina, Levin Mark-David, Visser Otto, Posthuma Eduardus F M, Doorduijn Jeanette K, Kater Arnon P, Dinmohamed Avinash G
Department of Research and Development Netherlands Comprehensive Cancer Organisation (IKNL) Utrecht The Netherlands.
Department of Internal Medicine Albert Schweitzer Hospital Dordrecht The Netherlands.
EJHaem. 2021 Dec 20;3(1):180-183. doi: 10.1002/jha2.368. eCollection 2022 Feb.
Studies on conditional relative survival (CRS) in chronic lymphocytic leukaemia (CLL) have hitherto been lacking in the literature. We predicted up-to-date estimates of 5-year RS at diagnosis and for each additional year survived (i.e., CRS) up to 15 years post-diagnosis among CLL patients diagnosed during 2007-2020. We showed that 5-year CRS continues to decline gradually with each additional year survived in a contemporary era with access to novel-based agents, irrespective of age. This finding indicates that CLL patients continue to experience substantial excess mortality compared to an age- and sex-matched group from the general population.
关于慢性淋巴细胞白血病（CLL）的条件相对生存率（CRS）的研究，迄今为止在文献中尚付阙如。我们预测了2007年至2020年期间确诊的CLL患者在诊断时以及确诊后存活的每一年直至15年的最新5年相对生存率（RS）估计值。我们发现，在可使用新型药物的当代，无论年龄如何，5年CRS会随着存活的每增加一年而继续逐渐下降。这一发现表明，与来自普通人群的年龄和性别匹配组相比，CLL患者仍然经历着显著的额外死亡率。
